4-{(tert-butoxycarbamoyl-methyl)-[5-(N,N'-bis-tert-butoxycarbonyl)guanidino-pentanoyl]amino}-benzoic acid methyl ester | 936571-60-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{(tert-butoxycarbamoyl-methyl)-[5-(N,N'-bis-tert-butoxycarbonyl)guanidino-pentanoyl]amino}-benzoic acid methyl ester
• CAS: 936571-60-7
• 化学式: C₃₀H₄₇N₅O₈
• 分子量: 605.732
• InChiKey: JAMQNNIAMRLUPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  43.0
• 可旋转键数：
  9.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  164.73
• 氢给体数：
  3.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  4-{(tert-butoxycarbamoyl-methyl)-[5-(N,N'-bis-tert-butoxycarbonyl)guanidino-pentanoyl]amino}-benzoic acid methyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-(5-(2,3-bis(tert-butoxycarbonyl)guanidino)-N-(2-(tert-butylamino)-2-oxoethyl)pentanamido)benzoic acid
  参考文献：
  名称：

  Modifications of the GSK3β substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics

  摘要：

  Amplification, overexpression, and elevated activation of Akt have been detected in many human malignancies making it an important target for cancer therapy. The Akt substrate-binding site offers a large number of potential interactions to an appropriately designed small molecule and can form the basis for the development of selective inhibitors. Here, we report the progression of GSK3 beta substrate-mimetic inhibitors towards the development of a potent, small molecule substrate-mimetic inhibitor of Akt. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.004
• 作为产物：
  描述：

  5-氨基颉草酸 在 caesium carbonate 、 达卡巴嗪 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 64.08h， 生成 4-{(tert-butoxycarbamoyl-methyl)-[5-(N,N'-bis-tert-butoxycarbonyl)guanidino-pentanoyl]amino}-benzoic acid methyl ester
  参考文献：
  名称：

  Modifications of the GSK3β substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics

  摘要：

  Amplification, overexpression, and elevated activation of Akt have been detected in many human malignancies making it an important target for cancer therapy. The Akt substrate-binding site offers a large number of potential interactions to an appropriately designed small molecule and can form the basis for the development of selective inhibitors. Here, we report the progression of GSK3 beta substrate-mimetic inhibitors towards the development of a potent, small molecule substrate-mimetic inhibitor of Akt. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.004